Transient ischemic attack after indirect revascularization surgery for pediatric patients with moyamoya disease: A retrospective study of intraoperative blood pressure

Anaesth Crit Care Pain MedPublished Retrospective cohort study

Authors' conclusion

Higher pre-induction baseline blood pressure and ipsilateral MRA score were independent risk factors predicting postoperative TIA in pediatric patients with moyamoya disease after indirect revascularization. The high variability and drastic decline in intraoperative MAP showed predictive value in postoperative symptom progression.

Study context

Population
Patients with moyamoya disease younger than 15 years undergoing indirect revascularization under GA, 2013–2019444 hemispheres
Participants
296 patients
Outcome
Postoperative TIA
Follow-up
Within 2 weeks after surgery
Methodological detailsmixed-effect logistic regression
  • Mixed-effect logistic regression

Main finding

As reported in the abstract

Postoperative TIA and its predictors

Postoperative TIA, cases (of 444 hemispheres)

70

16%

Baseline mean BP, aOR

1.261

95% CI 1.037–1.528P < 0.001

Average mean arterial pressure (MAP), aOR

1.137

95% CI 1.052–1.228P = 0.006

Ipsilateral magnetic resonance angiography (MRA) score, aOR

1.464

95% CI 0.886–2.419P = 0.012

Observational data: associations, not effects.

Further findings

Postoperative symptom progression and its predictors

Symptom progression, cases
34 (7.7%)
Average real variability of MAP (ARV-MAP), aOR
4.731 (95% CI 1.419-15.257; P = 0.003)
Maximum MAP declination (MaxD-MAP), aOR
1.271 (95% CI 1.013-1.520; P = 0.010)

Original publication

Transient ischemic attack after indirect revascularization surgery for pediatric patients with moyamoya disease: A retrospective study of intraoperative blood pressure. Anaesth Crit Care Pain Med. Published 26 October 2022. doi:10.1016/j.accpm.2022.101168

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.